How to buy Aldeyra Therapeutics stock | $7.11

Aldeyra Therapeutics, Inc is a biotechnology business based in the US. Aldeyra Therapeutics shares (ALDX) are listed on the NASDAQ and all prices are listed in US Dollars. Aldeyra Therapeutics employs 11 staff and has a market cap (total outstanding shares value) of USD$282.2 million.

How to buy shares in Aldeyra Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Aldeyra Therapeutics. Find the stock by name or ticker symbol: ALDX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aldeyra Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$7.11, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Aldeyra Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Aldeyra Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Aldeyra Therapeutics share price

Use our graph to track the performance of ALDX stocks over time.

Aldeyra Therapeutics shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$7.11
52-week range	USD$1.48 - USD$8.25
50-day moving average	USD$6.9991
200-day moving average	USD$6.4874
Wall St. target price	USD$26.6
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.998

Buy Aldeyra Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Aldeyra Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Aldeyra Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aldeyra Therapeutics price performance over time

Historical closes compared with the close of $7.11 from 2020-12-09

1 week (2021-01-08)	-31.04%
1 month (2020-12-16)	-2.47%
3 months (2020-10-15)	3.64%
6 months (2020-07-15)	21.96%

1 year (2020-01-15)	13.76%
2 years (2019-01-15)	-23.55%
3 years (2018-01-12)	3.80%
5 years (2016-01-15)	11.62%

Aldeyra Therapeutics financials

Gross profit TTM	USD$0
Return on assets TTM	-28.63%
Return on equity TTM	-65.68%
Profit margin	0%
Book value	$1.791
Market capitalisation	USD$282.2 million

TTM: trailing 12 months

Shorting Aldeyra Therapeutics shares

There are currently 1.5 million Aldeyra Therapeutics shares held short by investors – that's known as Aldeyra Therapeutics's "short interest". This figure is 3.3% down from 1.6 million last month.

There are a few different ways that this level of interest in shorting Aldeyra Therapeutics shares can be evaluated.

Aldeyra Therapeutics's "short interest ratio" (SIR)

Aldeyra Therapeutics's "short interest ratio" (SIR) is the quantity of Aldeyra Therapeutics shares currently shorted divided by the average quantity of Aldeyra Therapeutics shares traded daily (recently around 343501.33037694). Aldeyra Therapeutics's SIR currently stands at 4.51. In other words for every 100,000 Aldeyra Therapeutics shares traded daily on the market, roughly 4510 shares are currently held short.

However Aldeyra Therapeutics's short interest can also be evaluated against the total number of Aldeyra Therapeutics shares, or, against the total number of tradable Aldeyra Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aldeyra Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aldeyra Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0447% of the tradable shares (for every 100,000 tradable Aldeyra Therapeutics shares, roughly 45 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aldeyra Therapeutics.

Find out more about how you can short Aldeyra Therapeutics stock.

Aldeyra Therapeutics share dividends

We're not expecting Aldeyra Therapeutics to pay a dividend over the next 12 months.

Aldeyra Therapeutics share price volatility

Over the last 12 months, Aldeyra Therapeutics's shares have ranged in value from as little as $1.48 up to $8.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aldeyra Therapeutics's is 1.8961. This would suggest that Aldeyra Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aldeyra Therapeutics overview

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

Frequently asked questions

• What percentage of Aldeyra Therapeutics is owned by insiders or institutions?

  Currently 2.275% of Aldeyra Therapeutics shares are held by insiders and 67.312% by institutions.

• How many people work for Aldeyra Therapeutics?

  Latest data suggests 11 work at Aldeyra Therapeutics.

• When does the fiscal year end for Aldeyra Therapeutics?

  Aldeyra Therapeutics's fiscal year ends in December.

• Where is Aldeyra Therapeutics based?

  Aldeyra Therapeutics's address is: 131 Hartwell Avenue, Lexington, MA, United States, 02421

• What is Aldeyra Therapeutics's ISIN number?

  Aldeyra Therapeutics's international securities identification number is: US01438T1060

• What is Aldeyra Therapeutics's CUSIP number?

  Aldeyra Therapeutics's Committee on Uniform Securities Identification Procedures number is: 01438T106